Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a One-Two injection punch smooth frown lines better?

NCT ID NCT07756580

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Sep 10, 2026 · Updated 5 times

Summary

This early-stage trial is testing whether giving two different botulinum toxin injections in sequence can safely and effectively reduce moderate-to-severe frown lines between the eyebrows. About 120 healthy adults will receive an investigational drug called AGN-151586, followed by BOTOX either 14 or 21 days later. The study tracks side effects and how well the treatment smooths wrinkles over about five months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AGN-151586 and BOTOX (onabotulinumtoxinA) injections
What this could lead to
If successful, this could support a new treatment option for frown lines, potentially offering longer-lasting or more effective smoothing of glabellar lines.
What could go wrong
This is an early-phase study with a small number of participants, so results may not apply broadly. Injections can cause temporary side effects like bruising, pain, or drooping eyelids.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Moderate or severe glabellar lines (GL) at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale (FWS) at Screening and Baseline (Day 1) Visits * Must be in good health as per investigator's judgment based on medical history, physical examination, vital sign measurements, and 12-lead ECG parameters * Must have sufficient visual acuity without the use of eyeglasses (contact lens use is acceptable) to accurately assess their GL, in the opinion of the investigator. Exclusion Criteria: * Severe glabellar lines at rest as assessed by the investigator using the FWS * Prior exposure to botulinum neurotoxin of any serotype within the last 12 months prior to screening * History of hypersensitivity to any botulinum neurotoxin serotype or any other constituents of the study drug

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glabellar lines are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glabellar lines

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advanced Research Associates - Glendale /ID# 283833

    RECRUITING

    Glendale, Arizona, 85308, United States

  • Austin Institute for Clinical Research - Pflugerville /ID# 283817

    RECRUITING

    Pflugerville, Texas, 78660, United States

  • Etre, Cosmetic Dermatology And Laser Center /ID# 283831

    RECRUITING

    New Orleans, Louisiana, 70130, United States

  • Eye Research Foundation /ID# 283835

    RECRUITING

    Newport Beach, California, 92663, United States

  • Pacific Clinical Innovations /ID# 283812

    RECRUITING

    Vista, California, 92083, United States

  • Skincare Physicians /ID# 283851

    RECRUITING

    Chestnut Hill, Massachusetts, 02467, United States

  • Tennessee Clinical Research Center /ID# 283894

    RECRUITING

    Nashville, Tennessee, 37215, United States

  • Wilmington Dermatology Center /ID# 283853

    RECRUITING

    Wilmington, North Carolina, 28403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.